Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
about
Essential thrombocythemiaBone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-βInflammation as a Driver of Clonal Evolution in Myeloproliferative NeoplasmImpact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentPathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationAberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.Peripheral T-cell lymphoma presenting with rapidly progressing myelofibrosis.Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.Peripheral T cell lymphoma, not otherwise specified with myelofibrosis: report of a case with review of the literature.Mesenchymal Cell Reprogramming in Experimental MPLW515L Mouse Model of Myelofibrosis.TGF-beta1 induces bone marrow reticulin fibrosis in hairy cell leukemia.Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines.Oxidases and reactive oxygen species during hematopoiesis: a focus on megakaryocytes.Crucial factors of the inflammatory microenvironment (IL-1β/TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study.Homeostatic and pathogenic extramedullary hematopoiesis.Primary myelofibrosis and the "bad seeds in bad soil" concept.A possible role for STI571 in the treatment of idiopathic myelofibrosis.Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis.Anti-transforming growth factor-β therapy in patients with myelofibrosis.Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.Novel Therapies for Myelofibrosis.Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease.Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategyMegakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver
P2860
Q21202968-3D2123B8-2DDE-495B-8982-23EA9D3EAB7EQ26745943-E2C41C51-7101-47BA-B77E-9A8ADA990DF7Q26779936-1C4C1C28-178F-4249-AF28-C8C6C93500E2Q26779947-A221E8F3-1595-4A31-80C9-F0E2360D55CDQ26779960-874D4DF3-CE7B-4365-AC84-4383E358232BQ31149409-AD3C6CCC-13B3-45DC-9D38-029F68EA1613Q33347445-79843964-FE8B-46DD-8B8A-ACB563362DDEQ33753094-2C63EE07-92C2-45C7-951F-37072BE64501Q35741219-00556467-E527-45FF-8889-4837EB05961BQ36263805-D0D83551-72D7-49EC-872D-945B3A2B961EQ36441377-4E2B9106-0E15-44FA-8098-937989DD3C0AQ36512309-8ED0E955-47D8-43E5-80B2-739D1BE4E600Q37983798-0A0C0DB6-FA60-49B0-BDA3-7D6F7B4579DFQ39986585-A9763334-3862-4B64-BC63-9268234D0102Q40540089-21A6CFC7-D74D-431F-A957-922B79685FBBQ41838687-05B6E63E-F9C5-4777-9481-EB07D75D1313Q43739631-C1C39198-54A1-4B77-962B-55E431BDA10FQ44667229-8B65D37C-1AEE-4890-A54B-77F39717B721Q44667837-59DFEF35-85C3-48CE-A1AE-47E8264EF805Q48957526-51B153E2-0C63-4213-B8BC-C699E5BDAB2BQ50986633-3198D9A6-5E50-4B64-8E48-632142DC6F3CQ51737052-EC594730-3451-44E7-AEF1-E68D0E6F6C69Q52640385-ED93C3D6-0019-4976-A410-08E2E52FE605Q52817185-20CABC53-5BB8-4B66-A2BA-DA1CA366576AQ53133828-91B5B292-3E11-48E1-AA20-D322E2786F5EQ57116991-BCD4C4FB-5793-41AB-B64D-43941E5F649CQ58701086-97C09A68-A53A-40F6-85AA-CEBEC35FB008
P2860
Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Dual implication of fibrogenic ...... metaplasia with myelofibrosis.
@ast
Dual implication of fibrogenic ...... metaplasia with myelofibrosis.
@en
type
label
Dual implication of fibrogenic ...... metaplasia with myelofibrosis.
@ast
Dual implication of fibrogenic ...... metaplasia with myelofibrosis.
@en
prefLabel
Dual implication of fibrogenic ...... metaplasia with myelofibrosis.
@ast
Dual implication of fibrogenic ...... metaplasia with myelofibrosis.
@en
P356
P1433
P1476
Dual implication of fibrogenic ...... metaplasia with myelofibrosis.
@en
P2093
Le Bousse-Kerdilès MC
Martyré MC
P304
P356
10.1007/S002770050595
P577
1999-10-01T00:00:00Z